> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices/
- Published: 2019-11-03T12:00:00.000Z
- Updated: 2026-09-14T15:51:38.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145412

[**Hep D Virus Drug Development Guide**](https://www.fdaweb.com/hep-d-virus-drug-development-guide/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment.” 11/01/2019  

[**Draft Guide on Generic Drug User Fees**](https://www.fdaweb.com/draft-guide-on-generic-drug-user-fees/)  
*Federal Register* notice: FDA makes available a draft guidance entitled “Assessing User Fees under the Generic Drug User Fee Amendments of 2017.” 11/01/2019  

[**Panel to Review Correvio Atrial Fibrillation Drug**](https://www.fdaweb.com/panel-to-review-correvio-atrial-fibrillation-drug/)  
*Federal Register* notice: FDA has announced a 12/10 Cardiovascular and Renal Drugs Advisory Committee meeting to discuss a Correvio International NDA for its atrial fibrillation drug. 11/01/2019  

[**Mexitil Not Withdrawn Over Safety/Efficacy: FDA**](https://www.fdaweb.com/mexitil-not-withdrawn-over-safety-efficacy-fda/)  
*Federal Register* notice: FDA determines that Boehringer Ingelheim’s Mexitil (mexiletine hydrochloride) was not withdrawn from sale for safety or effectiveness reasons. 10/31/2019  

[**Meeting on Health Equity Related to Opioid Crisis**](https://www.fdaweb.com/meeting-on-health-equity-related-to-opioid-crisis/)  
*Federal Register* notice: FDA announces an 11/21 public meeting entitled “Office of Minority Health and Health Equity Public Meeting on Strategies to Improve Health Equity Amidst the Opioid Crisis.” 10/31/2019  

[**Draft Guide on IND Safety Report eSubmissions**](https://www.fdaweb.com/draft-guide-on-ind-safety-report-esubmissions/)  
*Federal Register* notice: FDA makes available a draft guidance on “Providing Regulatory Submissions in Electronic Format: IND Safety Reports.” 10/30/2019  

[**FDA Withdrawing Watson Labs Oxycodone Hydrochloride**](https://www.fdaweb.com/login.php?sa=v&aid=D5145358&cate=FR&stid=%241%24jq%2F.wK0.%243NUFrYO5rkZFJmqVXdEzg0)  
*Federal Register* notice: FDA proposes to withdraw approval of a Watson Laboratories ANDA for oxycodone hydrochloride and ibuprofen tablets and is announcing an opportunity for the holder of the ANDA to request a hearing on this action. 10/29/2019  

[**FDA Withdrawing InvaGen Trandolapril ANDA**](https://www.fdaweb.com/login.php?sa=v&aid=D5145360&cate=FR&stid=%241%24jq%2F.wK0.%243NUFrYO5rkZFJmqVXdEzg0)  
*Federal Register* notice: FDA proposes to withdraw approval of an InvaGen Pharmaceuticals ANDA for trandolapril tablets. 10/29/2019  

[**National Center for Toxicological Research Panel Meeting 12/3-4**](https://www.fdaweb.com/login.php?sa=v&aid=D5145359&cate=FR&stid=%241%24jq%2F.wK0.%243NUFrYO5rkZFJmqVXdEzg0)  
*Federal Register* notice: FDA announces a 12/3-4 Science Advisory Board to the National Center for Toxicological Research advisory committee meeting. 10/29/2019  

[**Class 1 for Continuous Glucose Monitor Data Systems**](https://www.fdaweb.com/login.php?sa=v&aid=D5145362&cate=FR&stid=%241%24jq%2F.wK0.%243NUFrYO5rkZFJmqVXdEzg0)  
*Federal Register* notice: FDA classifies continuous glucose monitor data management systems into Class 1 (general controls). 10/29/2019